hi Fluffy, smallcap Senetek (sntky/888791) füllt sich langsam mit viel Substanz:

Jeffrey M. Nugent, President and Chief Executive Officer of Revlon, Inc., said, "This agreement will both enhance our ability to create innovative products and accelerate the achievement of our strategic goal of making skin care a much more significant part of our overall business."

Revlon, Inc. is a worldwide cosmetics, skin care, fragrance, and personal care products company. The Company's vision is to become the world's most dynamic leader in global beauty and skin care. Revlon brands include Revlon(R), Almay(R), Ultima II(R), Charlie(R), and Flex(R), sold in approximately 175 countries and territories. www.revlon.com.

Senetek PLC is a science-driven biopharmaceutical company engaged in the development of products for dermatological therapeutics and the treatment of male and female sexual dysfunction. www.senetekplc.com.

The Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve risks and uncertainties including the risks detailed from time to time in the Company's Securities and Exchange Commission filings.

CONTACT: Richard Woods, 212-527-5791, or investors, Laura Kiernan, 212-527-5230, both for Revlon, Inc.; or Press and Investor Relations of Senetek PLC, 707-226-3900, ext. 102, or ir@senetek.net.

SOURCE Revlon, Inc.; Senetek PLC

CONTACT:          Richard Woods, 212-527-5791, or investors, Laura Kiernan,
                 212-527-5230, both for Revlon, Inc.; or Press and Investor Relations of
                 Senetek PLC, 707-226-3900, ext. 102, or ir@senetek.net
                 /Company News On-Call:  www.prnewswire.com/comp/115015.html or fax,
                 800-758-5804, ext. 115015

URL:              www.revlon.com
                 www.senetekplc.com
www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.


SOLLTE Analyst HEIKO THIEME MIT SEINEM KURSZIEL VON 10$ RECHT BEHALTEN????
ach wär das schön....
gruß storyhunter

NAPA, Calif., Jul 3, 2000 /PRNewswire via COMTEX/ -- Senetek PLC (Nasdaq:SNTKY) announced today that the U.S. Food and Drug Administration (FDA) has upgraded the status of the Invicorp(TM) IND to a partial clinical hold, allowing human studies to be conducted in the U.S. with a limited duration of three months and total number of doses not exceeding three per week. The FDA also recommended that the Company conduct a two-year rodent study of Invicorp(TM) as a result of previously reported brown adipose tissue proliferations observed in the course of a competitor's rodent study in which phentolamine mesylate, an ingredient formulated in low concentrations in Senetek's Invicorp(TM) product, was administered daily.

Senetek further announced that the New Zealand Medicines and Medical Devices Safety Authority has granted full approval for Invicorp(TM) for the treatment of Erectile Dysfunction (ED). Invicorp(TM) has been fully approved for use in Denmark since 1998 and is conditionally approved in the United Kingdom where it is currently available on a compassionate-use basis. The Committee on Safety of Medicines will meet in the U.K. in late July to review data provided by Senetek regarding the conditional approval and a response from the Medicines Control Agency is expected in August of this year. Senetek is seeking pan-European approval for Invicorp(TM) under the Mutual Recognition Process using Denmark as the reference member state.

Invicorp(TM) is a combination of vasoactive intestinal peptide (VIP) with 1 to 2 mg of phentolamine mesylate (PMS). This combination has shown excellent results in a wide range of patients, many having failed on other therapies for the treatment of ED. In completed Phase III clinical trials conducted in the United Kingdom, Denmark, Ireland and Australia, Invicorp(TM) demonstrated an efficacy level of 83% without serious side effects. The most frequently reported side effect was transient facial flushing, which typically subsided within minutes after use.

Unlike many other ED therapies, Invicorp(TM) has no known contraindications. Other significant advantages over existing therapies include: rapid onset of erection after stimulation -- typically within 2-5 minutes; the ability to induce an erection up to 2 1/2 hours after administration with natural termination of an erection after ejaculation, and efficacy in the treatment of organic Erectile Dysfunction. Invicorp(TM) is administered using a novel drug delivery system that renders the self-injection process uncomplicated and pain free.

Invicorp(TM) is currently prescribed on a named patient basis in the United Kingdom. It is estimated that more than 64,000 injections of Invicorp(TM) have been successfully administered by patients in the UK under this program.

Other products in Senetek's pipeline of treatments for sexual dysfunction include 17 patented novel compounds for the topical treatment of male and female sexual dysfunction. One of these compounds, Stearyl-Norleucine-VIP (SNV) has completed animal testing with no toxicity indications and is ready to enter Phase I clinical trials.

Senetek PLC is a science-driven biopharmaceutical company engaged in the development of products for dermatological therapeutics and the treatment of sexual dysfunction. www.senetekplc.com.

The Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve risks and uncertainties including the risks detailed from time to time in the Company's Securities and Exchange Commission filings.

   Contact:
   Investor Relations
   707-226-3900 x102
   ir@senetek.net

SOURCE Senetek PLC
CONTACT:          Investor Relations of Senetek PLC, 707-226-3900, ext. 102, or
                 ir@senetek.net
                 /Company News On-Call:  www.prnewswire.com/comp/115015.html or fax,
                 800-758-5804, ext. 115015

URL:              www.senetekplc.com
www.prnewswire.com

ICH HALTE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!10$!!!!!!!!!!!!!!!!!!!­
so long
sh